27 U.S. Cities Where Stocks Yield 26% a Year

From Investing Daily | Ad

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

Get in on the action here.

FUSN Insider Trading (Fusion Pharmaceuticals)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.12%

Insider Buying (Last 12 Months): $71,203.71

Insider Selling (Last 12 Months): $517,191.81

Fusion Pharmaceuticals Insider Trading History Chart

Fusion Pharmaceuticals Share Price & Price History

^$2.53

▲ +0.04 (1.61%)

As of 07/1/2022 04:59 PM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Click here now!

Fusion Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/27/2022	John Valliant	CEO	Sell	4,511	$6.03	$27,201.33	318,147
4/25/2022	John Valliant	CEO	Sell	2,036	$6.03	$12,277.08	324,805
4/20/2022	John Valliant	CEO	Sell	367	$6.02	$2,209.34	327,763
4/13/2022	John Valliant	CEO	Sell	11,994	$6.41	$76,881.54	328,130
4/11/2022	John Valliant	CEO	Sell	2,600	$7.37	$19,162.00	358,379
4/8/2022	John Valliant	CEO	Sell	826	$7.52	$6,211.52	360,979
4/6/2022	John Valliant	CEO	Sell	100	$7.58	$758.00	360,979
3/30/2022	John Valliant	CEO	Sell	300	$7.52	$2,256.00
3/28/2022	John Valliant	CEO	Sell	9,600	$7.55	$72,480.00
3/25/2022	John Valliant	CEO	Sell	500	$7.42	$3,710.00
3/23/2022	John Valliant	CEO	Sell	100	$7.50	$750.00
3/21/2022	John Valliant	CEO	Sell	1,500	$7.47	$11,205.00
3/17/2022	John Valliant	CEO	Sell	900	$7.51	$6,759.00
3/7/2022	John Valliant	CEO	Sell	3,100	$6.99	$21,669.00
3/4/2022	John Valliant	CEO	Sell	8,400	$7.32	$61,488.00
2/28/2022	John Valliant	CEO	Sell	3,100	$7.40	$22,940.00
2/24/2022	John Valliant	CEO	Sell	2,500	$7.41	$18,525.00
2/22/2022	John Valliant	CEO	Sell	4,100	$7.85	$32,185.00
2/17/2022	John Valliant	CEO	Sell	1,700	$7.98	$13,566.00
2/15/2022	John Valliant	CEO	Sell	12,600	$8.33	$104,958.00
8/23/2021	Steven Gannon	Director	Buy	2,829	$7.99	$22,603.71	12,000
8/16/2021	Steven Gannon	Director	Buy	6,000	$8.10	$48,600.00	6,000
12/23/2020	Adams Street Partners Llc	Major Shareholder	Sell	4,569	$12.39	$56,609.91
6/30/2020	Johnson & Johnson	Major Shareholder	Buy	725,000	$17.00	$12,325,000.00

Trading Isn’t Getting Easier–But Options Just Did!

From Tradewins | Ad

Options trading expert and trading champion Chuck Hughes has done it again with his guide, “Options Trading Made Easy”!

Made for new traders, this guide explains options–plus the consistent profits you could make–in easy to understand terms.

Don’t keep waiting for it to get easier–get the e-book here!

>>>

SEC Filings (Institutional Ownership Changes) for Fusion Pharmaceuticals (NASDAQ:FUSN)

64.25% of Fusion Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Fusion Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/16/2022	Woodline Partners LP	25,703	$0.20M	0.0%	-89.4%	0.059%
5/16/2022	UBS Group AG	21,300	$0.17M	0.0%	+45,219.1%	0.049%
5/13/2022	Federated Hermes Inc.	3,055,037	$23.74M	0.1%	+94.1%	7.049%
5/4/2022	Victory Capital Management Inc.	183,690	$1.30M	0.0%	-26.6%	0.424%
2/25/2022	AlphaCentric Advisors LLC	100,000	$0.42M	0.1%	N/A	0.232%
2/14/2022	Perceptive Advisors LLC	1,227,017	$5.12M	0.1%	-2.2%	2.849%
2/14/2022	Point72 Asset Management L.P.	1,048,956	$4.37M	0.0%	+22.3%	2.436%
2/7/2022	Victory Capital Management Inc.	250,380	$1.04M	0.0%	-6.5%	0.581%
12/3/2021	Perceptive Advisors LLC	1,254,607	$9.94M	0.1%	-29.3%	2.913%
11/15/2021	Point72 Asset Management L.P.	858,012	$6.80M	0.0%	-2.0%	1.992%
11/15/2021	Sectoral Asset Management Inc	38,198	$0.30M	0.0%	N/A	0.089%
11/12/2021	Johnson & Johnson	3,670,516	$29.07M	2.6%	N/A	8.523%
11/9/2021	BlackRock Inc.	414,256	$3.28M	0.0%	-11.9%	0.963%
11/2/2021	Victory Capital Management Inc.	267,703	$2.12M	0.0%	-0.7%	0.622%
8/17/2021	Woodline Partners LP	154,597	$1.25M	0.0%	+24.1%	0.364%
8/17/2021	Perceptive Advisors LLC	1,775,167	$14.34M	0.2%	-9.0%	4.181%
8/16/2021	Point72 Asset Management L.P.	875,141	$7.07M	0.0%	+16.7%	2.061%
8/16/2021	Perceptive Advisors LLC	1,775,167	$14.34M	0.2%	-9.0%	4.181%
8/16/2021	Federated Hermes Inc.	597,841	$4.83M	0.0%	+5.8%	1.408%
8/16/2021	Goldman Sachs Group Inc.	18,221	$0.15M	0.0%	+29.5%	0.043%
8/13/2021	Adams Street Partners LLC	2,973,744	$24.03M	5.0%	-0.5%	7.004%
8/13/2021	FMR LLC	3,184,209	$25.73M	0.0%	+1.5%	7.500%
8/11/2021	BlackRock Inc.	470,303	$3.80M	0.0%	-41.8%	1.108%
8/3/2021	Victory Capital Management Inc.	269,623	$2.18M	0.0%	-5.6%	0.635%
5/18/2021	Millennium Management LLC	10,726	$0.12M	0.0%	-76.9%	0.025%
5/18/2021	Point72 Asset Management L.P.	750,000	$8.04M	0.0%	+36.4%	1.766%
5/18/2021	Morgan Stanley	76,171	$0.82M	0.0%	+90.7%	0.179%
5/17/2021	Perceptive Advisors LLC	1,950,167	$20.91M	0.3%	-12.8%	4.593%
5/17/2021	Woodline Partners LP	124,594	$1.34M	0.0%	+135.9%	0.293%
5/13/2021	Federated Hermes Inc.	565,000	$6.06M	0.0%	+7.6%	1.331%
5/10/2021	Adams Street Partners LLC	2,989,644	$32.05M	5.1%	-14.4%	7.044%
5/7/2021	BlackRock Inc.	807,536	$8.66M	0.0%	-2.8%	1.903%
5/7/2021	Altfest L J & Co. Inc.	10,139	$0.11M	0.0%	N/A	0.024%
5/4/2021	Victory Capital Management Inc.	285,678	$3.06M	0.0%	+59.1%	0.673%
3/12/2021	DekaBank Deutsche Girozentrale	13,000	$0.16M	0.0%	N/A	0.031%
3/2/2021	Norges Bank	50,000	$0.59M	0.0%	N/A	0.120%
2/16/2021	Clough Capital Partners L P	399,399	$4.69M	0.3%	-0.8%	0.957%
2/12/2021	Caas Capital Management LP	23,148	$0.27M	0.0%	-60.4%	0.055%
2/12/2021	Federated Hermes Inc.	525,000	$6.17M	0.0%	+2.9%	1.258%
2/9/2021	Pivotal bioVenture Partners Investment Advisor LLC	1,598,379	$18.78M	6.2%	N/A	3.831%
2/5/2021	BlackRock Inc.	830,737	$9.76M	0.0%	+80.6%	1.991%
2/1/2021	Victory Capital Management Inc.	179,524	$2.11M	0.0%	+18.4%	0.430%
12/30/2020	Deerfield Management Company L.P. Series C	972,046	$11.68M	0.2%	-22.7%	2.330%
11/13/2020	Morgan Stanley	26,693	$0.32M	0.0%	-96.0%	0.064%
11/12/2020	Federated Hermes Inc.	510,000	$6.13M	0.0%	+59.4%	1.224%
11/9/2020	Caas Capital Management LP	58,398	$0.70M	0.0%	-2.7%	0.140%
11/9/2020	Victory Capital Management Inc.	151,608	$1.82M	0.0%	-17.5%	0.364%
11/6/2020	BlackRock Inc.	459,918	$5.53M	0.0%	+1.5%	1.104%
8/18/2020	Blackstone Group Inc	60,000	$1.05M	0.0%	N/A	0.144%
8/17/2020	Perceptive Advisors LLC	2,235,983	$35.96M	0.6%	N/A	5.367%
8/14/2020	Orbimed Advisors LLC	3,224,770	$56.34M	0.8%	N/A	7.740%
8/14/2020	Canada Pension Plan Investment Board	3,116,966	$54.45M	0.1%	N/A	7.481%
8/14/2020	Deerfield Management Company L.P. Series C	1,257,000	$21.96M	0.6%	N/A	3.017%
8/14/2020	Point72 Hong Kong Ltd	8,019	$0.14M	0.0%	N/A	0.019%
8/14/2020	Point72 Europe London LLP	2,000	$35K	0.0%	N/A	0.005%
8/14/2020	Point72 Asset Management L.P.	60,000	$1.05M	0.0%	N/A	0.144%
8/14/2020	TPG Group Holdings SBS Advisors Inc.	2,551,794	$44.58M	0.8%	N/A	6.125%
8/14/2020	Tudor Investment Corp Et Al	29,145	$0.51M	0.0%	N/A	0.070%
8/14/2020	Avidity Partners Management LP	164,554	$2.88M	0.2%	N/A	0.395%
8/14/2020	Logos Global Management LP	121,128	$2.12M	0.4%	N/A	0.291%
8/14/2020	Jefferies Group LLC	175,800	$3.07M	0.0%	N/A	0.422%
8/14/2020	Alyeska Investment Group L.P.	75,600	$1.32M	0.0%	N/A	0.181%
8/13/2020	FMR LLC	3,038,998	$53.09M	0.0%	N/A	7.295%
8/13/2020	Federated Hermes Inc.	320,000	$5.59M	0.0%	N/A	0.768%
8/12/2020	Johnson & Johnson Innovation JJDC Inc.	3,670,516	$64.12M	12.6%	N/A	8.810%
8/11/2020	Monashee Investment Management LLC	50,000	$0.87M	0.1%	N/A	0.120%
7/31/2020	UBS Group AG	5,484	$96K	0.0%	N/A	0.013%

Data available starting January 2016

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Today's Range

Now: $2.53

$2.50

$2.54

50 Day Range

MA: $3.78

$2.49

$5.42

52 Week Range

Now: $2.53

$2.41

$9.50

Volume

307 shs

Average Volume

33,062 shs

Market Capitalization

$109.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Fusion Pharmaceuticals?: Fusion Pharmaceuticals' top insider shareholders include:
John Valliant (CEO)
Steven Gannon (Director)
Adams Street Partners Llc (Major Shareholder)
Learn More about top insider investors at Fusion Pharmaceuticals.

Tailor an Options Trading Strategy to Fit Your Needs

From RJO Futures | Ad

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Download your FREE Options Strategy Guide Today.